232 related articles for article (PubMed ID: 30213802)
21. Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias.
Gregory KJ; Hall NE; Tobin AB; Sexton PM; Christopoulos A
J Biol Chem; 2010 Mar; 285(10):7459-74. PubMed ID: 20051519
[TBL] [Abstract][Full Text] [Related]
22. Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors.
Lanzafame AA; Sexton PM; Christopoulos A
Mol Pharmacol; 2006 Aug; 70(2):736-46. PubMed ID: 16709648
[TBL] [Abstract][Full Text] [Related]
23. Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors.
Tränkle C; Weyand O; Voigtländer U; Mynett A; Lazareno S; Birdsall NJ; Mohr K
Mol Pharmacol; 2003 Jul; 64(1):180-90. PubMed ID: 12815174
[TBL] [Abstract][Full Text] [Related]
24. Characterization of the novel positive allosteric modulator, LY2119620, at the muscarinic M(2) and M(4) receptors.
Croy CH; Schober DA; Xiao H; Quets A; Christopoulos A; Felder CC
Mol Pharmacol; 2014 Jul; 86(1):106-15. PubMed ID: 24807965
[TBL] [Abstract][Full Text] [Related]
25. Probing the selectivity of allosteric modulators of muscarinic receptors at other G-protein-coupled receptors.
Pfaffendorf M; Batink HD; Tränkle C; Mohr K; van Zwieten PA
J Auton Pharmacol; 2000 Feb; 20(1):55-62. PubMed ID: 11048962
[TBL] [Abstract][Full Text] [Related]
26. Structure-Activity Relationships of Pan-Gα
Berizzi AE; Bender AM; Lindsley CW; Conn PJ; Sexton PM; Langmead CJ; Christopoulos A
ACS Chem Neurosci; 2018 Jul; 9(7):1818-1828. PubMed ID: 29683647
[TBL] [Abstract][Full Text] [Related]
27. Bisquaternary dimers of strychnine and brucine. A new class of potent enhancers of antagonist binding to muscarinic M2 receptors.
Zlotos DP; Buller S; Holzgrabe U; Mohr K
Bioorg Med Chem; 2003 Jun; 11(12):2627-34. PubMed ID: 12757728
[TBL] [Abstract][Full Text] [Related]
28. Mutagenesis of nucleophilic residues near the orthosteric binding pocket of M1 and M2 muscarinic receptors: effect on the binding of nitrogen mustard analogs of acetylcholine and McN-A-343.
Suga H; Sawyer GW; Ehlert FJ
Mol Pharmacol; 2010 Oct; 78(4):745-55. PubMed ID: 20643905
[TBL] [Abstract][Full Text] [Related]
29. Binding of orthosteric ligands to the allosteric site of the M(2) muscarinic cholinergic receptor.
Redka DS; Pisterzi LF; Wells JW
Mol Pharmacol; 2008 Sep; 74(3):834-43. PubMed ID: 18552124
[TBL] [Abstract][Full Text] [Related]
30. Atypical muscarinic allosteric modulation: cooperativity between modulators and their atypical binding topology in muscarinic M2 and M2/M5 chimeric receptors.
Tränkle C; Dittmann A; Schulz U; Weyand O; Buller S; Jöhren K; Heller E; Birdsall NJ; Holzgrabe U; Ellis J; Höltje HD; Mohr K
Mol Pharmacol; 2005 Dec; 68(6):1597-610. PubMed ID: 16157694
[TBL] [Abstract][Full Text] [Related]
31. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors.
Lazareno S; Birdsall NJ
Mol Pharmacol; 1995 Aug; 48(2):362-78. PubMed ID: 7651370
[TBL] [Abstract][Full Text] [Related]
32. Autoantibodies enhance agonist action and binding to cardiac muscarinic receptors in chronic Chagas' disease.
Hernandez CC; Nascimento JH; Chaves EA; Costa PC; Masuda MO; Kurtenbach E; Campos DE Carvalho AC; Gimenez LE
J Recept Signal Transduct Res; 2008; 28(4):375-401. PubMed ID: 18702010
[TBL] [Abstract][Full Text] [Related]
33. Complex allosteric modulation of cardiac muscarinic receptors by protamine: potential model for putative endogenous ligands.
Hu J; Wang SZ; Forray C; el-Fakahany EE
Mol Pharmacol; 1992 Aug; 42(2):311-21. PubMed ID: 1513329
[TBL] [Abstract][Full Text] [Related]
34. Investigating the interaction of McN-A-343 with the M2 muscarinic receptor using its nitrogen mustard derivative.
Suga H; Ehlert FJ
Biochem Pharmacol; 2010 Apr; 79(7):1025-35. PubMed ID: 19913516
[TBL] [Abstract][Full Text] [Related]
35. Identification of a Novel Allosteric Site at the M
Burger WAC; Gentry PR; Berizzi AE; Vuckovic Z; van der Westhuizen ET; Thompson G; Yeasmin M; Lindsley CW; Sexton PM; Langmead CJ; Tobin AB; Christopoulos A; Valant C; Thal DM
ACS Chem Neurosci; 2021 Aug; 12(16):3112-3123. PubMed ID: 34351123
[TBL] [Abstract][Full Text] [Related]
36. Importance of receptor expression in the classification of novel ligands at the M
Jiang Y; Yeasmin M; Gondin AB; Christopoulos A; Valant C; Burger WAC; Thal DM
Br J Pharmacol; 2024 Jul; 181(14):2338-2350. PubMed ID: 36550621
[TBL] [Abstract][Full Text] [Related]
37. Regulation of signal transduction at M2 muscarinic receptor.
Krejcí A; Michal P; Jakubík J; Rícný J; Dolezal V
Physiol Res; 2004; 53 Suppl 1():S131-40. PubMed ID: 15119944
[TBL] [Abstract][Full Text] [Related]
38. The impact of orthosteric radioligand depletion on the quantification of allosteric modulator interactions.
Avlani VA; McLoughlin DJ; Sexton PM; Christopoulos A
J Pharmacol Exp Ther; 2008 Jun; 325(3):927-34. PubMed ID: 18322151
[TBL] [Abstract][Full Text] [Related]
39. Allosteric modulation in monomers and oligomers of a G protein-coupled receptor.
Shivnaraine RV; Kelly B; Sankar KS; Redka DS; Han YR; Huang F; Elmslie G; Pinto D; Li Y; Rocheleau JV; Gradinaru CC; Ellis J; Wells JW
Elife; 2016 May; 5():. PubMed ID: 27151542
[TBL] [Abstract][Full Text] [Related]
40. Allostery of atypical modulators at oligomeric G protein-coupled receptors.
Shivnaraine RV; Kelly B; Elmslie G; Huang XP; Dong YJ; Seidenberg M; Wells JW; Ellis J
Sci Rep; 2021 Apr; 11(1):9265. PubMed ID: 33927236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
